Zobrazeno 1 - 10
of 39
pro vyhledávání: ''
Autor:
Hélène Senellart, Sung Bae Kim, Takashi Kojima, Antoine Adenis, Shukui Qin, Peter C. Enzinger, Jaafar Bennouna, Jia Chen, Toshihiko Doi, Jean-Philippe Metges, Ken Kato, Lin Shen, Christelle De La Fouchardiere, Kei Muro, Eric Francois, Toshikazu Moriwaki, Keynote Investigators, S. Peter Kang, Shailaja Suryawanshi, Se-Hoon Lee, Ruixue Wang, Raed Al-Rajabi, Florian Lordick, Paula Ferreira, Gustavo Girotto, Chih-Hung Hsu, Manish A. Shah, Pooja Bhagia
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(35)
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metast
Autor:
Masakazu Toi, Joyce O'Shaughnessy, Investigators, Valentina Guarneri, Ran Wei, Maarten Hulstijn, Irfan Cicin, Mario Campone, Frances M. Boyle, Jens Huober, Patrick Neven, Erika Hamilton, Belen San Antonio, Morihito Okada, Sara M. Tolaney, Andrew M Wardley, Roberto Hegg, Desiree Headley, Stephen R. D. Johnston, Martin Frenzel, Q. Zhang, Priya Rastogi, Zhi Min Shao, Jorge Luis Martinez Rodriguez, Miguel Martín, Javier Cortes, Ian C. Smith, Nadia Harbeck, Joohyuk Sohn, Joanne Cox
Publikováno v:
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology
Càncer de mama precoç; Teràpia endocrina; Abemaciclib Cáncer de mama precoz; Terapia endocrina; Abemaciclib Early Breast Cancer; Endocrine Therapy; Abemaciclib PURPOSE Many patients with HR+, HER2− early breast cancer (EBC) will not experience
Autor:
Ang Li, Jason C. Chandler, Davey B. Daniel, Félix Couture, Sunil Babu, Vijay Gunuganti, Maen A. Hussein, Robert M. Jotte, Samer Kasbari, Michael McCleod, Edward B. Garon, Justin N. Baker, Nivedita Aanur, Lawrence H. Einhorn, Leora Horn, Ben C. Creelan, Petros Nikolinakos, George P. Keogh, David R. Spigel, Craig Reynolds, Natasha B. Leighl, David M. Waterhouse, George R. Blumenschein
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(33)
PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-y
Autor:
Mahmut Gumus, Alexander Luft, Parneet Cheema, Keynote Investigators, Julien Mazieres, M. Catherine Pietanza, Victoria Ebiana, Maya Gottfried, Mirjana Wollner, Francisco Orlandi, Hye Ryun Kim, Solange Peters, Tibor Csőszi, James Chih-Hsin Yang, Yiwen Luo, Charles M. Rudin, Alejandro Navarro, Delvys Rodriguez-Abreu, Gregory P. Kalemkerian, Terufumi Kato, Mark M. Awad
Publikováno v:
J Clin Oncol
PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for
Autor:
Norihiko Ikeda, Katsuo Yoshiya, Isamu Okamoto, Koichi Goto, Takeharu Yamanaka, Nobuyuki Yamamoto, Hiroaki Okamoto, Toshiaki Takahashi, Hideo Saka, Kohei Yokoi, Tsuyoshi Ueno, Tetsuya Mitsudomi, Hiroshi Date, Yuichi Takiguchi, Masahiro Tsuboi, Hirotsugu Kenmotsu, Shinichi Toyooka, Kenji Sugio, Takashi Seto, Haruko Daga
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(19)
PURPOSE To evaluate the efficacy of pemetrexed plus cisplatin versus vinorelbine plus cisplatin as postoperative adjuvant chemotherapy in patients with pathologic stage II-IIIA nonsquamous non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS We
Autor:
Takashi Kojima, Masako Asayama, Yosuke Togashi, Yuichi Mikamoto, Naoki Takahashi, Masashi Wakabayashi, Akihito Kawazoe, Hitomi Tamura, Nami Hirano, Shota Fukuoka, Akihiro Sato, Takeshi Kuwata, Kohei Shitara, Takako Yoshii, Shogo Nomura, Hiroyoshi Nishikawa, Daisuke Kotani, Hiroki Hara
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(18)
PURPOSE This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal cancer. PATIENTS AND METHODS Enrolled patients received regorafenib plus nivolumab in a dose-finding part to estimate the maximum tolerated dose. Additional pat
Autor:
Ragini R. Kudchadkar, Uwe M. Martens, Paul Nghiem, Robert L. Ferris, Julie E. Stein, Junchen Gu, Suzanne L. Topalian, Michi M. Shinohara, Adam Barrows, Christine H. Chung, Rima M. Kulikauskas, Jean Pierre Delord, Lara Dunn, Andrea Horvath, Janis M. Taube, Shailender Bhatia, Lot A. Devriese, William H. Sharfman, Bin Li, Céleste Lebbé, Tian Chen, Asim Amin, Elizabeth L. Engle, Christopher D. Lao
Publikováno v:
J Clin Oncol
PURPOSE Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is often upregulated in MCC, and
Autor:
Heather A. Lankes, Sudarshan K. Sharma, Carol Aghajanian, Cara Mathews, Daniel J. Powell, Dmitriy Zamarin, Andrea R. Hagemann, Oliver Zivanovic, Camille C. Gunderson, Emily M. Ko, Samir N. Khleif, Robert A. Burger, Michael W. Sill, Michael Feldman
Publikováno v:
J Clin Oncol
PURPOSE Single-agent PD-1 blockade exhibits limited efficacy in epithelial ovarian cancer (EOC). We evaluated ipilimumab plus nivolumab compared with nivolumab alone in women with persistent or recurrent EOC. METHODS Eligibility criteria included mea
Autor:
Shuichi Hironaka, Hiroaki Tanioka, Kazuhiro Nishikawa, Yoshiki Horie, Junji Kawada, Takeharu Yamanaka, Kei Muro, Toshikazu Moriwaki, Hiroyasu Ishida, Tomomi Kashiwada, Ayumu Hosokawa, Taito Esaki, Narikazu Boku, Akihito Tsuji, Kentaro Yamazaki, Hiroshi Tsukuda, Yasutaka Sukawa, Keita Uchino, K. Shinozaki, Akitaka Makiyama, Ichinosuke Hyodo, Hirofumi Yasui
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(17)
PURPOSE This study evaluated the continuous use of trastuzumab beyond progression (TBP) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. PATIENTS AND METHODS Patients with HER2-
Autor:
John Wu, Andrew G. Hill, Michael Millward, Catherine Barrow, Christopher Jackson, Michael P. Brown, William F. Patterson, Wendy Huang, Zhiyu Tang, Victoria Atkinson, Gary Richardson, Hui K Gan, Ben Tran, Yunxin Chen, Dewan Zeng, Lisa G. Horvath, Lusong Luo, Andrew Haydon, Michael B. Jameson, Lai Wang, Ben Markman, Jayesh Desai, Stephen Begbie, Phillip Parente, Adnan Nagrial, Benjamin Solomon, Michael Friedlander
Publikováno v:
Journal of Clinical Oncology
PURPOSE Lifirafenib is an investigational, reversible inhibitor of B-RAFV600E, wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, and efficacy of lifirafenib